Infant Deaths Associated with Cough and Cold Medications -Two States, 2005
Cough and cold medications that contain nasal decongestants, antihistamines, cough suppressants, and expectorants commonly are used alone or in combination in attempts to temporarily relieve symptoms of upper respiratory tract infection in children aged <2 years. However, during [2004] [2005] , an estimated 1,519 children aged <2 years were treated in U.S. emergency departments for adverse events, including overdoses, associated with cough and cold medications.* In response to reports of infant deaths after such events, CDC and the National Association of Medical Examiners (NAME) investigated deaths in U.S. infants aged <12 months associated with cough and cold medications. This report describes the results of that investigation, which identified deaths of three infants aged <6 months in 2005, for which cough and cold medications were determined by medical examiners or coroners to be the underlying cause. The dosages at which cough and cold medications can cause illness or death in children aged <2 years are not known. Food and Drug Administration (FDA)-approved dosing recommendations for clinicians prescribing cough and cold medications do not exist for this age group. Because of the risks for toxicity, absence of dosing recommendations, and limited published evidence of effectiveness of these medications in children aged <2 years, parents and other caregivers should not administer cough and cold medications to children in this age group without first consulting health-care provider and should follow the provider's instructions precisely (1) . Clinicians should use caution when prescribing cough and cold medications to children aged <2 years. Moreover, clinicians should always ask caregivers about their use of over-the-counter combination medications to avoid overdose in children from multiple medications that contain the same ingredient.
In January 2006, NAME, in collaboration with CDC, initiated an e-mail inquiry, requesting reports of deaths in infants aged <12 months for which cough and cold medications were determined as the underlying cause. To identify additional cases, CDC examined media and medical-journal reports of infant deaths suspected to be linked to cough and cold medications during 2005. A total of 15 local medical examiners in 12 U.S. states and Canada responded to the NAME survey. However, no cases other than those from media and published reports were identified. From these reports, CDC identified three cases of infant deaths in two states during 2005 that were determined by a medical examiner or coroner to have been caused by cough and cold medications ( Table 1) .
The three infants ranged in age from 1 to 6 months; two were male. All three infants had what appeared to be high levels of pseudoephedrine (a nasal decongestant) in postmortem blood samples. The blood levels of pseudoephedrine ranged from 4,743 ng/mL to 7,100 ng/mL. † One infant (patient 2) had received both a prescription and an over-thecounter cough and cold combination medication at the same time; both medications contained pseudoephedrine ( Table 1) .
The other two infants also had received pseudoephedrinecontaining medications (one prescription and one over the counter). Two of the infants (patients 1 and 2) had been administered prescription medications containing carbinoxamine (an antihistamine), although neither had detectable postmortem blood levels of carbinoxamine. Two of the infants (patients 2 and 3) had detectable blood levels of dextromethorphan (a cough suppressant) and acetaminophen (an antipyretic and analgesic).
All three infants were found dead in their homes. Autopsy and medical investigation records were obtained. A medical examiner or coroner determined that cough and cold medication was the underlying cause of death for each of the three. None of the deaths were determined to be intentional. On autopsy, two of the infants (patients 1 and 2) had evidence of respiratory infection; no abnormalities in cardiac pathology were revealed in any of the infants.
and other over-the-counter cough medications for young children because of associated morbidity and mortality (8) .
In addition to advising caregivers and health-care providers regarding the risks of administering cough and cold medications to children aged <2 years, public health officials have taken steps to improve the safety of these medications. On June 8, 2006 , FDA took enforcement action to stop the manufacture of carbinoxamine-containing medications that had not been approved by the agency; FDA noted that many of the medications were inappropriately labeled for use in infants and young children despite safety concerns regarding use of carbinoxamine in children aged <2 years (9) . Although manufacturers were required to cease production by September 6, 2006 , some products might still be in distribution. In another action, the availability of pseudoephedrinecontaining medications has been affected by the federal Combat Methamphetamine Epidemic Act, which was signed into law March 9, 2006 . This act bans over-the-counter sales (but permits behind-the-counter sales in limited amounts) of cold medications that contain pseudoephedrine, which can be used to make methamphetamine. Because of this act, pseudoephedrine has been removed as an ingredient in many cough and cold medications and replaced with other nasal decongestants. However, some pediatric cough and cold medications containing pseudoephedrine still might be sold behind the counter. As an alternative to pseudoephedrine and other nasal decongestants, caregivers might consider clearing nasal congestion in infants with a rubber suction bulb; secretions can be softened with saline nose drops or a cool-mist humidifier.
Few data exist regarding the therapeutic or toxic levels of cough and cold medications in children aged <2 years (2, 3, 10) . Blood levels of cough and cold medications revealed in postmortem studies might not reflect levels in the bloodstream at the time of administration (1) . However, in this report, the blood levels of pseudoephedrine found in the three patients aged 1-6 months were approximately nine to 14 times the levels resulting from administration of recommended doses to children aged 2-12 years.
The findings in this report are subject to at least two limitations. First, because no universally accepted criteria exist for attributing deaths to cough and cold medications, the cause of death in these cases was based on the report of the medical examiner or coroner. However, the actual cause of death might have been overdose of one drug, interaction of different drugs, an underlying medical condition, or a combination of drugs and underlying medical conditions. Second, the findings are limited by the low response rate and absence of identified cases from the NAME survey, which might underestimate the number of deaths in infants attributed to cough and cold medications.
No FDA-approved dosing recommendations exist for administering over-the-counter cough and cold medications to children aged <2 years, and proper dosing for children in this age group has not been studied. Instructions on over-thecounter medications advise consumers to "consult a doctor" for children in this age group (1) . Suggested dosing for some cough and cold medications can be found in parenting and prescribing guides, and clinicians commonly extrapolate a dose based on the weight or age of children aged <2 years from dosing guidelines for adults and older children (7) . Such extrapolation is based on the assumption that the pathophysiology of the disease and the effects of the drug are similar in adult and pediatric patients.
Caregivers and clinicians should be aware of the risk for serious illness or fatal overdose from administration of cough and cold medications to children aged <2 years. Caregivers should only administer cough and cold medications to children in this age group when following the exact advice of a clinician. Clinicians should be certain that caregivers understand 1) the importance of administering cough and cold medications only as directed and 2) the risk for overdose if they administer additional medications that might contain the same ingredient. Caregivers should always inform their health-care providers of all medications they are administering to a child. (2) , and that increase is expected to continue because of the aging of the population and increases in obesity and physical inactivity. These findings signal the need for broader implementation of effective public health interventions, such as arthritis and chronic disease selfmanagement programs, which can reduce medical expenditures (3) among persons with AORC.
National and State Medical
National direct and indirect costs were derived from the household component of the 2003 MEPS (MEPS-HC), an annual household interview survey of medical conditions, medical system expenditures and utilization, and earnings and employment history (4) . MEPS is designed to be representative of the U.S. civilian, noninstitutionalized population; each year's MEPS panel is a subsample of the previous year's National Health Interview Survey. The 2003 MEPS did not include a nursing home component; thus, costs among nursing home residents were excluded from the analysis. During the household interview, MEPS respondents described all medical conditions for which they had sought care from a health-care provider. Each of these medical conditions was later assigned an International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) code by medical coders. The 2003 MEPS-HC response rate was 71.9%. AORC cases in MEPS were identified using three-digit ICD-9-CM codes selected by the National Arthritis Data Workgroup* (5). The 2003 MEPS sample consisted of 23,352 participants aged >18 years, and 4,801 participants met the case definition for AORC.
Direct per-person costs attributable to AORC were estimated using a series of four-stage regression analyses (6) that modeled the probability and magnitude of medical care expenditures among adults aged >18 years. This modeling included adjustment for the following variables: age (18-44, 45-64, or >65 years), sex, race (white or nonwhite), ethnicity (Hispanic or non-Hispanic), marital status (single, currently married, widowed, separated, or divorced), highest educational attainment (less than high school, high school graduate, some college, college graduate, or graduate school), health-insurance status (no insurance, public insurance only, or any private insurance), and the presence of nine other high-cost chronic conditions (hypertension, other forms of heart disease, pulmonary disease, stroke, other neurologic conditions, diabetes, cancer, mental illness, or non-AORC musculoskeletal conditions). The average per-person direct cost attributable to AORC was the difference between the observed and corresponding expected medical costs. Expected costs simulated costs among persons with AORC as if they did not have AORC (2) . Average per-person direct costs were generated for overall expenditures and for each of the following four cost categories: 1) ambulatory care, 2) emergency department and inpatient services, 3) prescriptions, and 4) other costs (i.e., home health care, vision aids, dental visits, and medical devices). Finally, total national direct costs were calculated as the product of the number of persons aged >18 years reporting AORC and the average per-person direct costs.
Indirect per-person costs attributable to AORC were derived from a similar four-stage analysis that modeled the probability of employment and the magnitude of lost earnings among persons aged 18-64 years. However, age was categorized differently (18-34, 35-44, 45-54, and 55-64 years), and no adjustment was made for health-insurance status. Total indirect costs were the product of the number of persons aged 18-64 years with AORC who had ever worked and the average lost earnings per person attributable to AORC. All analyses were conducted using statistical software that adjusted for the clustered sampling design of MEPS. The statistical methods used to derive the national direct and indirect cost estimates are described elsewhere (2 The increase in total direct costs resulted from the increase in the number of persons (9 million) with AORC in 2003, attributable to the increase in population (predominantly in the ages 45-64 years cohort) and the increased prevalence of self-reported AORC among adults aged >50 years (2) . The findings in this report are subject to at least two limitations. First, direct costs likely were underestimated because MEPS does not capture costs associated with complementary and alternative medicines (persons with arthritis are among the major consumers of these medicines [7] ), long-term mental health services, and nondurable medical goods. Similarly, indirect costs did not capture loss of unpaid work such as homemaking, child care, and volunteer work. Other expenses associated with treatment of illness, such as transportation, accommodation, and lost wages among family members were not measured by MEPS and therefore were not included in this analysis. Second, state-specific direct and indirect cost estimates were simply derived using state-level prevalences and were not adjusted for differences among states in provider charges, treatment resources, or wage differentials. Thus, costs among states with medical expenditures or wages higher than the national mean likely are underestimated, and costs among those below the mean overestimated. Deriving cost estimates from state-level MEPS data was not possible because these data were available for only 30 of the largest states.
The substantially increased costs of AORC in 2003 were driven by an increase in number of persons with AORC. Costs likely will continue rising because the number of persons with arthritis is projected to continue to increase, with another 8 million arthritis cases anticipated during 2005-2015 (8) . Without cost-reduction strategies, the economic burden of AORC will continue to increase. This trend underscores the need for wide-scale implementation of interventions that reduce medical expenditures and lost earnings among persons with AORC. Self-management programs such as the Arthritis Self-Help Program are cost-effective strategies to reduce direct costs associated with arthritis (3). Self-management programs foster skills in coordinating work accommodations and pain management (through physical activity and weight management) and are essential for reducing the economic and societal burden of AORC.
Suicide Trends and Characteristics Among Persons in the Guaraní Kaiowá and Ñandeva Communities -Mato Grosso do Sul, Brazil, 2000-2005
Suicide rates among indigenous communities around the world vary substantially; in many nations these groups have the highest suicide risk of any identifiable cultural or ethnic group (1). Mato Grosso do Sul is a state in the southwest corner of Brazil that borders Bolivia and Paraguay. In 2004, the Guaraní, an indigenous ethnic group in the region (Figure 1 ), accounted for 2.6% of Mato Grosso do Sul's population (approximately 2,230,702).* During 1975-2000, the infant mortality rate decreased, and overall life expectancy increased in Mato Grosso do Sul; however, suicide increased as a proportion of overall mortality among the Kaiowá and Ñandeva communities of the Guaraní population (2) . In 2000, the National Health Foundation (FUNASA) of the Brazilian Ministry of Health (BMH) initiated a study of suicide trends and characteristics in these two Guaraní communities; data were collected during 2000-2005, and epidemiologic assistance was provided by CDC. This report summarizes the results of that study, which suggested that the suicide rate among Guaraní was 19 times higher than the national rate in Brazil and 10 times higher than the rate in Mato Grosso do Sul and that suicides disproportionately affected Guaraní adolescents and young adults. To decrease suicide rates, BMH initiated research and prevention programs among the Guaraní, and the Guaraní initiated measures to increase their economic self-sufficiency. Participants in the study were from the Kaiowá and Ñandeva communities of the Guaraní population, collectively referred to as Guaraní in this report. FUNASA medical teams determined cause of death using categories from the International Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) (3). Suicide was defined as a death resulting from purposely self-inflicted poisoning or injury corresponding to ICD-10 codes X60-X84 and Y87. Demographic data on Guaraní were drawn from routinely updated census information such as name, sex, date of birth, ethnicity, address, village, Special Indigenous Sanitary District (DSEI), and municipality. As part of an ongoing ethnographic study, an anthropologist obtained qualitative information on each death through interviews with persons who included political and spiritual leaders of the communities. Participants were asked questions about the decedent (e.g., observations of decedent's behavior) and the community (e.g., social or environmental conditions that might have been associated with the suicide). Among the Guaraní in 2000, information on age was available for all but seven cases of suicide, and information on sex was available for all but one case. Demographic data for deaths in other years were complete. Crude rates and age-and sexspecific rates were calculated per 100,000 population.
During 2000-2005, a total of 3,004 deaths were recorded in the Guaraní population in Mato Grasso do Sul, including 286 (9.5%) suicides; 190 (66.7%) of the suicide victims were male. All but three suicides were caused by suffocation (hanging); three were caused by pesticide ingestion. Annual suicide rates in the Guaraní ranged from 121. 5 Editorial Note: The findings in this report indicate that youths and young adults in Guaraní communities had higher suicide rates than older members of their population and that the Guaraní suicide rate overall was higher than the rates in Mato Grosso do Sul and Brazil overall. In the United States, suicide rates among some American Indian and Alaska Native (AI/AN) indigenous populations have been similar to those of the overall U.S. population, whereas in certain other AI/AN populations, rates have been seven times higher than the U.S. rate overall (5). Historically, the highest suicide rate nationally in Brazil has been among those aged >65 years (6) . However, among the Guaraní, the highest rates were among adolescents and young adults. Among Guaraní aged 20-29 years, the 2005 suicide rate was 159.9 per 100,000 population, compared with 6.1 for the same age group nationwide in 2004 (4).
Previous studies have identified multiple factors that might be associated with suicidal behaviors among the Guaraní. These factors, some resulting from colonization, include rapid sociocultural change, disturbances in traditional social life, progressive dismantling of extended family structure, and forced relocation to reservations (7) . Exposure to different and conflicting cultures, perspectives, and belief systems exacerbates challenges faced by these communities and contributes to intergenerational conflict. Studies conducted among other indigenous communities indicate that youths often perceive themselves as marginalized from mainstream society and their own communities (7), resulting in a sense of social isolation that might contribute to an increased rate of suicide.
The findings in this report are subject to at least four limitations. First, counting the number of suicides based on death certificates might underestimate the true number because of misclassification of cause of death (8) . Many decedents were buried privately by their families; in 2000, 16.5% of deaths among the Guaraní occurred without medical attention or certification by a coroner or medical examiner, so the cause of death could not be established. In 2001, DSEI began providing financial support for burials, thereby increasing death registrations, and by 2003, cause of death could not be established for only 5.7% of deaths. Second, because data were not specifically collected at the municipal or national level, suicide rates of indigenous and nonindigenous populations could not be compared. Third, temporal data were limited and insufficient for comprehensive analysis. Finally, the small absolute number of suicides in the Guaraní limited the detail of this analysis.
Suicide is a complex, multifaceted problem influenced by risk factors among persons, families, communities, and societies. Studies on indigenous populations in other nations have found that community-based, comprehensive suicideprevention programs are the most promising (9) . Such programs vary, but strategies typically include counseling, support groups, crisis response, recreational activities, volunteer support systems, and cultural-heritage education. For example, a suicide-prevention program for an American Indian community in the United States included a comprehensive strategy involving schools, community outreach to persons at risk for suicide and their families, improved infrastructure of local mental health services, and interventions addressing common suicide risk factors in the community (e.g., alcohol abuse, family violence, and unemployment) (10) .
To better address health disparities among indigenous communities, BMH established DSEI and placed multidisciplinary indigenous health-care teams in municipal governments. These teams periodically visit area villages and, with the support of trained local residents, provide health care. In 2000, FUNASA began a mental health initiative to address alcohol abuse and suicidal behaviors in indigenous ethnic communities. This initiative involved developing the Monitoring Center for Indigenous Mental Health, which includes physicians, behavioral scientists, social workers, and linguists. The center supports research and encourages a multidisciplinary approach to assessing and preventing suicidal behavior. Its projects are developed with community participation and designed so that they can be sustained by the local community. In addition, the Guaraní have been organizing to recover, through court challenges and legislation, most of their former territories; this is expected to increase their economic self-sufficiency and reduce poverty and unemployment, improvements associated with decreased risk for suicide and suicidal behaviors (9) .
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Changes to National Notifiable Infectious Disease List and Data Presentation, as of January 2007
This issue of MMWR incorporates modifications to Table I and Table II Two new conditions have been added to the list of nationally notifiable infectious diseases: nonparalytic poliovirus infection and vibriosis (non-cholera Vibrio species infections). Incidence data for both of these conditions will appear in Table I . The surveillance case definitions adopted for these conditions are listed within their respective CSTE position statements (1, 2) and are posted to the case definitions section of the National Notifiable Diseases Surveillance System (NNDSS) website (3).
Modifications to
The CSTE position statement, "Enhancing local, state, and territorial-based surveillance for invasive pneumococcal disease in children less than five years of age" (4), includes reporting guidelines for the surveillance case definitions for drug-resistant Streptococcus pneumoniae invasive disease (DRSP) (event code 11720) and Streptococcus pneumoniae invasive disease in children aged <5 years (event code 11717). In the weekly NNDSS provisional data tables published in MMWR, DRSP data will be displayed in Table II in two columns: one column for DRSP of any age and a second column for DRSP in children aged <5 years.
Modifications to Figure I
Rubella has been deleted from Figure I and replaced with giardiasis. Rubella has been deleted because of low incidence and its designation as no longer endemic in the United States (5,6). Giardiasis, a gastrointestinal illness, is caused by the protozoan parasite Giardia intestinalis. This pathogen has a low infectious dose, protracted communicability, and moderate resistance to chlorine, which makes it ideally suited for transmission through drinking and recreational water, food, and both person-to-person and animal-to-person contact. Transmission of giardiasis occurs throughout the United States with a marked seasonality peaking in summer through early fall (7). Session 1 includes an overview of general immunization concepts and principles and vaccine safety, storage and handling, and administration. Session 2 topics include pertussis, pneumococcal disease (childhood), polio, rotavirus, and Haemophilus influenzae type b. Session 3 topics include measles, rubella, varicella, zoster, and meningococcal disease. Session 4 topics include hepatitis B, hepatitis A, influenza, human papillomavirus, and pneumococcal disease (adult). A live questionand-answer session will be conducted via toll-free telephone lines. Continuing Education (CE) credits will be provided.
Additional information regarding the series is available at http:// www2.cdc.gov/phtn/epv07/default.asp. Information for site administrators regarding establishing and registering a viewing location is available at http://www.cdc.gov/phtnonline. This website also is appropriate for individual participants who wish to register to view the broadcast from a specific location, or who seek CE credit. No registration is necessary to access the webcasts via an Internet connection. The link to the live webcasts is available at http://www2.cdc.gov/phtn/webcast/epv07/default.asp. The webcasts will be accessible through an Internet connection until March 15, 2007. The program will become available as a self-study DVD and Internet-based program in March 2007. Table II . † † Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed). Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV , which appears quarterly. § § Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases (proposed). A total of two cases were reported for the 2006-07 flu season. ¶ ¶ No measles cases were reported for the current week. *** Data for meningococcal disease (all serogroups) are available in Table II . † † † No rubella cases were reported for the current week. § § § Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed). 3  9  2 9  3  9  3  2 3  4 2  3  6  4  9  1 9  4  7  Delaware  -0  2  ---1  4  ---0  2  -1  District of Columbia  -0  1  ---0  2  ---0  5  --Florida  3  4  13  3  7  3  8  16  3  4  3  3  10  3  2  Georgia  -1  6  ---3  8  -1  1  0  3 -29  117  -20  2  6  14  2  4  2  4  14  2  1  Delaware  -7 28 2  3  10  2  -2  4  13  2  3  2  5  16  2  8  Alaska  -0  1  ---0  4  -1  -0  1  --California  2  3  8  2  --3  8  -2  2  3  10  2 49  250  489  49  244  22  123  239  22  38  1  34  118  1  30 New England -2 2 5 3 - 4  18  43  4  24  11  41  183  11  14  -17  68  -29  Delaware  -0 157  735  1,355  157  897  3  55  141  3  84  89  254  477  89  185 New England  -20  487  -487  -2  73  -73  -3  70  -70  Connecticut  -0  479  -479  -0  72  -72  -0  64  -64  Maine§   -2  1 0  -1  -0  8  ---0  2  --Massachusetts  -15  53  -7  -1  9  -1  -2  11  -6  New Hampshire  -4 25 1  66  179  1  12  -1  21  --3  35  71  3  3  Arkansas  -15  47  -1  -0  7  ---2  9  --Louisiana  -13  42  -7  -0  0  ---1  25  --Oklahoma  1  8  40  1  --0  17  ---2  9  --Texas§   -31  102  -4  -2  13  --3  29  53  3  3   Mountain  21  50  88  21  23  -4  17  -1  4  25  87  4  6  Arizona  4  17  41  4  2  -2  13  --3  12  35  3  -Colorado  16  12  30  16  12  -1  8  -1  1  3  15  1 25  114  181  25  55  -4  17  -3  7  37  87  7  15  Alaska  1  1  7  1  1  -0  0  ---0  2  --California  22  88  158  22  47  -0  0  --5  30  76  5  13  Hawaii  -5  16  -1  -0  2  ---1  4  -2  Oregon§   2  8  1 6  2  6  -0  1  --2  1  3 2  2  -Washington  -10  39  ---2  12  ---2  13 -- 26  22  40  26  35  5  2  8  5  3  20  40  73  20  27  Delaware  -0  0  ---0  0  ---0  3  -1  District of Columbia  -0  3  ---0  2  ---2  8  -1  Florida  16  12  29  16  12  5  2  8  5  3  13  14  23  13  13  Georgia  10  7  28  10  23  -0  1  ---7 15  188  556  15  22  -0  58  ---0  26  --Arkansas  -12  88  -9  -0  4  ---0  2  --Louisiana  1  1  8  1  1  -0  13  ---0  9  --Oklahoma  -0  0  ---0  6  ---0  4  --Texas¶   14  167  549  14  12  -0  38  ---0  16  --Mountain  8  61  137  8  45  -0  57  ---1  228  --Arizona  -0  0  ---0  0  ---0  15  --Colorado  5  30  76  5  36  -0  10  ---0  51  --Idaho¶   -0  0  ---0  3 
New England
N 0 0 N N 1 1 7 1 - Idaho § - 51 253 - 50 N 0 0 N N - 0 0 - - Montana § - 46 143 - 9 N 0 0 N N - 0 26 - - Nevada § - 87 397 - 62 - 1 4 - - - 0 1 - - New Mexico § - 191 339 - 281 - 0 3 - - - 0 5 - - Utah - 94 180 - 28 - 1 3 - - - 0 3 - - Wyoming § 7 2 7 5 4 7 2 8 - 0 1 - - - 0 1 1 - -N 0 0 N N - 0 0 - - American Samoa U 0 46 U U U 0 0 U U U 0 0 U U C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U Guam - 0 0 - - - 0 0 - - - 0 0 - - Puerto Rico 95 95 198 95 16 N 0 0 N N N 0 0 N N U.S. Virgin Islands U 5 16 U U U 0 0 U U U 0 0 U U- 3 1 2 - 3 - 3 2 0 - 5 - 0 1 - - Montana § - 2 1 1 - 1 - 3 2 0 - 1 - 0 0 - - Nevada § - 1 9 - 1 - 23 135 - 19 - 0 1 - - New Mexico § - 1 6 - 1 -American Samoa U 0 0 U U U 0 2 U U U 0 0 U U C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U Guam - 0 0 - - - 0 0 - - - 0 0 - - Puerto Rico - 1 12 - - 5 5 16 5 2 - 0 0 - - U.S. Virgin Islands U 0 0 U U U 1 5 U U U 0 0 U UNew England - 2 2 0 - 6 - 2 8 - 2 - 2 1 2 - 1 Connecticut - 1 2 - - - 0 3 - 2 - 0 9 - - Maine § - 0 2 - - - 0 2 - - - 0 2 - - Massachusetts - 0 6 - 6 - 0 5 - - - 0 4 - 1 New Hampshire - 0 16 - - - 0 1 - - - 0 1 - - Rhode Island § - 0 2 - - - 0 4 - - - 0 6 - - Vermont § - 0 2 - - - 0 1 - - - 0 2 - - Mid. Atlantic - 6 18 - 6 - 8 20 - 15 1 13 51 1 9 New Jersey - 2 5 - 3 - 2 8 - 5 - 1 11 - 1 New York (Upstate) - 1 8 - - - 1 5 - - 1 6 30 1 - New York City - 2 10 - 2 - 2 5 - 3 - 2 16 - 2 Pennsylvania - 1 5 - 1 - 3 9 - 7 - 5 19 - 6 E.N. Central - 6 13 - 7 3 7 16 3 7 - 8 26 - 4 Illinois - 1 4 - 2 - 1 7 - 1 - 0 3 - 3 Indiana - 0 5 - - - 0 7 - - - 0 4 - - Michigan - 2 7 - 3 - 3 6 - 5 - 3 11 - 1 Ohio - 1 4 - 1 3 2 10 3 1 - 3 19 - - Wisconsin - 1 4 - 1 - 0 2 - - - 0 5 - - W.N. Central - 2 8 - 3 - 3 9 - 1 - 1 1 5 - 3 Iowa - 0 1 - - - 0 3 - - - 0 3 - - Kansas - 0 5 - 2 - 0 2 - - - 0 2 - - Minnesota - 0 7 - - - 0 5 - - - 0 11 - - Missouri - 1 3 - 1 - 1 6 - 1 - 0 3 - 3 Nebraska § - 0 2 - - - 0 3 - - - 0 2 - - North Dakota - 0 0 - - - 0 0 - - - 0 0 - - South Dakota - 0 3 - - - 0 1 - - - 0 1 - -
S. Atlantic
1 1 Maryland § - 1 6 - 2 - 2 9 - - - 2 7 - 1 North Carolina - 0 20 - - - 0 23 - - - 0 5 - 2 South Carolina § - 0 3 - - - 2 4 - 1 - 0 1 - - Virginia § - 1 7 - - - 1 4 - - - 1 5 - - West Virginia - 0 3 - - - 0 7 - - - 0 3 - - E.S. Central 1 2 8 1 1 1 7 2 1 1 3 1 2 9 1 - Alabama § - 0 3 - - - 2 1 3 - 1 - 0 2 - - Kentucky 1 0 5 1 - - 1 5 - 1 1 0 5 1 - Mississippi - 0 1 - - - 1 4 - - - 0 2 - - Tennessee § - 1 5 - 1 1 2 7 1 1 - 1 7 - - W.S. Central - 6 2 0 - - - 1 6 3 5 - 1 - 0 1 2 - - Arkansas - 0 9 - - - 1 3 - - - 0 1 - - Louisiana - 0 4 - - - 0 5 - 1 - 0 2 - - Oklahoma - 0 3 - - - 0 14 - - - 0 6 - - Texas § - 5 1 5 - - - 1 2 2 6 - - - 0 1 2 - - Mountain - 5 1 7 - 2 - 2 9 - 1 - 2 8 - - Arizona - 3 16 - - - 0 4 - - - 1 4 - - Colorado - 1 3 - 1 - 0 4 - - - 0 2 - - Idaho § - 0 2 - - - 0 2 - 1 - 0 3 - - Montana § - 0 3 - - - 0 0 - - - 0 1 - - Nevada § - 0 2 - - - 0 5 - - - 0 2 - - New Mexico § - 0 2 - - - 0 2 - - - 0 1 - - Utah - 0 2 - 1 - 0 5 - - - 0 6 - - Wyoming § - 0 1 - - - 0 1 - - - 0 0 - - Pacific 2 1 6 5 3 2 2 0 3 1 1 2 5 3 1 - 1 9 - - Alaska - 0 0 - - 1 0 3 1 - - 0 0 - - California 1 14 48 1 20 1 8 20 1 1 - 1 9 - - Hawaii - 0 3 - - - 0 1 - - - 0 0 - - Oregon § 1 1 4 1 - 1 1 5 1 - N 0 0 N N Washington - 1 4 - - - 1 6 - - - 0 0 - - American Samoa U 0 0 U U U 0 0 U U U 0 0 U U C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U Guam - 0 0 - - - 0 0 - - - 0 0 - - Puerto Rico - 0 6 - - - 0 4 - - - 0 1 - - U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U U4 - 0 6 - - - 1 3 - 1 Connecticut - 8 227 - - - 0 3 - - - 0 2 - - Maine § - 2 3 4 - 2 - 0 1 - - - 0 2 - 1 Massachusetts - 0 3 - 2 - 0 3 - - - 0 2 - - New Hampshire - 3 95 - - - 0 3 - - - 0 2 - - Rhode Island § - 0 9 3 - - - 0 1 - - - 0 1 - - Vermont § - 1 1 5 - - - 0 1 - - - 0 1 - -
Mid. Atlantic
16 131 556 16 43 1 5 13 1 4 -3 11 -5 New Jersey -27 184 -16 -0 3 -2 -0 2 --New York (Upstate) 16 59 250 16 1 1 1 71 - - 0 4 - - New York City - 0 18 - - - 3 9 - 1 - 1 4 - 2 Pennsylvania - 36 231 - 26 - 1 4 - 1 - 0 4 - 3 E.N. Central - 10 151 - 4 1 2 7 1 4 2 2 12 2 7 Illinois - 0 0 - - - 1 5 - 2 - 0 4 - 4 Indiana - 0 3 - - - 0 3 - - - 0 5 - - Michigan - 1 5 - - - 0 2 - - - 0 3 - 1 Ohio - 1 5 - 1 1 0 3 1 - 2 1 4 2 1 Wisconsin - 10 147 - 3 - 0 2 - 2 - 0 2 - 1 W.N. Central 1 5 1 6 9 1 - - 0 1 4 - 2 - 1 4 - 1 Iowa - 1 8 - - - 0 1 - - - 0 2 - - Kansas 1 0 2 1 - - 0 2 - - - 0 1 - - Minnesota - 2 167 - - - 0 12 - - - 0 3 - - Missouri - 0 2 - - - 0 1 - 1 - 0 2 - - Nebraska § - 0 2 - - - 0 1 - - - 0 2 - 1 North Dakota - 0 0 - - - 0 1 - - - 0 1 - - South Dakota - 0 1 - - - 0 1 - 1 - 0 1 - -
S. Atlantic
- 5 - 0 1 - - - 0 1 - - District of Columbia - 0 7 - 1 - 0 2 - - - 0 1 - - Florida - 1 5 - - 2 1 4 2 1 1 2 7 1 1 Georgia - 0 1 - - - 2 6 - 3 1 0 3 1 - Maryland § - 1 3 7 4 - 1 2 - 1 5 - - - 0 2 - - North Carolina - 0 4 - 2 - 0 4 - - - 0 11 - - South Carolina § - 0 2 - - - 0 2 - - - 0 2 - - Virginia § - 4 2 9 - - - 1 4 - - - 0 4 - - West Virginia - 0 3 - - - 0 1 - - - 0 2 - - E.S. Central - 0 3 - - - 0 3 - - - 1 3 - - Alabama § - 0 3 - - - 0 2 - - - 0 2 - - Kentucky - 0 2 - - - 0 1 - - - 0 1 - - Mississippi - 0 1 - - - 0 1 - - - 0 1 - - Tennessee § - 0 2 - - - 0 2 - - - 0 2 - - W.S. Central - 0 3 - - - 1 7 - - - 1 4 - 1 Arkansas - 0 0 - - - 0 2 - - - 0 1 - 1 Louisiana - 0 0 - - - 0 1 - - - 0 2 - - Oklahoma - 0 0 - - - 0 2 - - - 0 3 - - Texas § - 0 3 - - - 1 6 - - - 0 3 - - Mountain - 0 3 - - - 1 6 - - - 1 5 - 3 Arizona - 0 2 - - - 0 3 - - - 0 3 - 1 Colorado - 0 1 - - - 0 2 - - - 0 2 - 1 Idaho § - 0 2 - - - 0 1 - - - 0 1 - - Montana § - 0 0 - - - 0 1 - - - 0 1 - - Nevada § - 0 1 - - - 0 1 - - - 0 1 - - New Mexico § - 0 1 - - - 0 1 - - - 0 1 - - Utah - 0 1 - - - 0 2 - - - 0 1 - 1 Wyoming § - 0 1 - - - 0 0 - - - 0 2 - - Pacific1 Hawaii N 0 0 N N - 0 2 - - - 0 2 - - Oregon § - 0 2 - - 2 0 2 2 - - 0 7 - 7 Washington - 0 1 - - - 0 3 - - - 0 5 - - American Samoa U 0 0 U U U 0 0 U U U 0 0 - - C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 - - Guam - 0 0 - - - 0 0 - - - 0 0 - - Puerto Rico N 0 0 N N - 0 1 - - - 0 1 - - U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 - -
United States
3 8 4 1 2 2 6 4 2 - 0 1 - - Connecticut - 1 9 - 3 4 3 14 4 - - 0 0 - - Maine † - 1 1 2 - 3 - 2 8 - - - 0 0 - - Massachusetts - 12 30 - 30 - 3 17 - 2 - 0 1 - - New Hampshire - 2 27 - - - 1 5 - - - 0 1 - - Rhode Island † - 0 1 1 - - - 0 3 - - - 0 1 - - Vermont † - 2 1 4 - 2 - 1 5 - - - 0 0 - - Mid.- 1 5 - 1 - 0 1 - - Minnesota - 0 56 - - - 0 6 - - - 0 2 - - Missouri - 5 14 - 12 - 1 6 - - - 2 12 - - Nebraska † - 2 9 - 3 - 0 0 - - - 0 5 - - North Dakota - 0 9 - - - 0 7 - - - 0 0 - - South Dakota - 0 4 - - - 0 4 - 1 - 0 0 - -
S. Atlantic
1 - 1 - 0 0 - - - 0 3 - - District of Columbia - 0 2 - - - 0 0 - - - 0 1 - - Florida 4 4 20 4 4 2 0 167 2 - - 0 5 - - Georgia - 0 3 - 2 - 5 10 - 3 - 1 5 - - Maryland † - 2 9 - 6 - 6 1 3 - 2 - 1 6 - -- 3 1 1 - 3 - 3 1 1 - 3 - 0 5 - - Virginia † - 2 1 9 - - - 1 1 2 7 - - - 2 1 3 - - West Virginia - 0 9 - - - 2 7 - - - 0 2 - - E.S. Central - 6 28 - 6 - 4 16 - - - 6 31 - 1 Alabama † - 2 1 9 - 2 - 1 8 - - - 2 1 1 - - Kentucky - 0 5 - - - 0 4 - - - 0 1 - - Mississippi - 0 4 - 2 - 0 2 - - - 0 1 - - Tennessee † - 3 1 1 - 2 - 2 9 - - - 4 2 2 - 1 W.S. Central - 1 7 3 5 - - 1 9 3 4 1 7 - 1 2 7 - - Arkansas - 1 7 - - - 0 5 - 1 - 0 10 - - Louisiana - 0 1 - - - 0 0 - - - 0 1 - - Oklahoma - 0 9 - - 1 0 9 1 - - 0 18 - - Texas † - 1 5 3 2 - - - 9 2 9 - 6 - 0 4 - - Mountain 8 4 5 8 8 8 4 6 - 3 2 7 - - 1 0 5 1 - Arizona - 7 29 - 1 - 2 10 - - - 0 2 - - Colorado 8 10 40 8 26 - 0 0 - - 1 0 1 1 - Idaho † - 1 8 - 2 - 0 2 5 - - - 0 3 - - Montana † - 2 9 - 2 - 0 2 - - - 0 2 - - Nevada † - 0 9 - 9 - 0 1 - - - 0 1 - - New Mexico † - 2 8 - 2 - 0 2 - - - 0 2 - - Utah - 13 39 - 4 - 0 1 - - - 0 2 - - Wyoming † - 1 8 - - - 0 2 - - - 0 1 - - Pacific 1 27 228 1 11 - 3 12 - - - 0 1 - - Alaska 1 1 7 1 - - 0 4 - - - 0 0 - - California - 21 225 - - - 3 11 - - - 0 1 - - Hawaii - 1 6 - 6 - 0 0 - - - 0 0 - - Oregon † - 2 8 - 5 - 0 4 - - - 0 1 - - Washington - 5 46 - - - 0 0 - - - 0 0 - - American Samoa U 0 0 U U U 0 0 U U U 0 0 U U C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U Guam - 0 0 - - - 0 0 - - - 0 0 - - Puerto Rico - 0 1 - - - 1 6 - - N 0 0 N N U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U U
United States
- - - 0 3 - - - 0 2 - - Rhode Island § - 1 1 0 - - - 0 2 - - - 0 3 - - Vermont § - 1 6 - - - 0 1 - - - 0 2 - - Mid.1 Idaho § - 3 9 - - - 1 7 - - - 0 3 - - Montana § - 2 1 0 - 1 - 0 0 - - - 0 1 3 - - Nevada § - 3 2 0 - 1 - 0 5 - - - 1 2 0 - - New Mexico § - 4 1 5 - 5 - 0 1 - - - 2 1 5 - 4 Utah 1 5 15 1 2 - 1 14 - - - 1 6 - 1 Wyoming § - 1 4 - - - 0 3 - - - 0 1 9 - - PacificAmerican Samoa U 0 0 U U U 0 0 U U U 0 0 U U C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U Guam - 0 0 - - - 0 0 - - - 0 0 - - Puerto Rico - 4 18 - - - 0 0 - - - 0 2 - - U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U U
New England
- 3 1 5 - 3 - 1 4 - - Connecticut U 0 0 U - U 0 0 U U Maine § - 0 2 - 1 - 0 2 - - Massachusetts - 2 6 - 2 - 0 4 - - New Hampshire - 0 9 - - - 0 4 - - Rhode Island § - 0 2 - - - 0 3 - - Vermont § - 0 2 - - - 0 0 - - Mid.2 1 0 - - Iowa N 0 0 N N - 0 0 - - Kansas 1 1 5 1 2 - 0 3 - - Minnesota - 0 52 - - - 0 7 - - Missouri - 1 5 - - - 0 2 - - Nebraska § - 0 4 - 1 - 0 2 - - North Dakota - 0 2 - - - 0 1 - - South Dakota - 0 2 - - - 0 0 - - S. Atlantic 6 2 3 4 5 6 2 0 4 1 6 4 - Delaware - 0 2 - 1 - 0 0 - - District of Columbia - 0 2 - 1 - 0 1 - - Florida - 5 16 - 5 - 0 0 - - Georgia 3 5 12 3 6 2 0 0 2 - Maryland § 3 4 1 2 3 5 2 1 5 2 - North Carolina - 0 26 - - U 0 0 U U South Carolina § - 1 6 - 2 - 0 0 - - Virginia § - 2 9 - - - 0 0 - - West Virginia - 0 6 - - - 0 2 - - E.S. Central 3 3 1 1 3 6 - 0 2 - 2 Alabama § N 0 0 N N - 0 0 - - Kentucky - 0 5 - 1 - 0 0 - - Mississippi - 0 0 - - - 0 2 - 2 Tennessee § 3 3 9 3 5 - 0 0 - - W.S. Central 2 7 1 8 2 - 1 3 8 1 - Arkansas - 0 5 - - - 0 2 - - Louisiana - 0 2 - - - 0 1 - - Oklahoma 2 2 8 2 - 1 1 5 1 - Texas § - 4 1 4 - - - 2 6 - - Mountain 9 1 1 4 1 9 5 - 3 1 2 - 3 Arizona 1 5 34 1 1 - 2 9 - - Colorado 7 2 7 7 4 - 1 4 - 3 Idaho § - 0 1 - - - 0 1 - - Montana § - 0 0 - - - 0 0 - - Nevada § - 0 0 - - - 0 0 - - New Mexico § - 1 5 - - - 0 3 - - Utah 1 1 7 1 - - 0 0 - - Wyoming § - 0 1 - - - 0 0 - - Pacific 1 2 9 1 1 - 0 1 - - Alaska - 0 0 - - - 0 0 - - California - 0 0 - - - 0 0 - - Hawaii 1 2 9 1 1 - 0 1 - - Oregon § N 0 0 N N - 0 0 - - Washington N 0 0 N N - 0 0 - - American Samoa U 0 0 U U U 0 0 U U C.N.M.I. U 0 0 U U U 0 0 U U Guam - 0 0 - - - 0 0 - - Puerto Rico N 0 0 N N - 0 0 - - U.S. Virgin Islands U 0 0 U U U 0 0 U U C.N.New England - 0 3 - - - 0 1 - - 1 4 1 0 1 1 Connecticut U 0 0 U - - 0 0 - - - 0 6 - - Maine § - 0 2 - N - 0 1 - - - 0 2 - - Massachusetts - 0 0 - - - 0 0 - - 1 2 7 1 1 New Hampshire - 0 0 - - - 0 0 - - - 0 2 - - Rhode Island § - 0 2 - - - 0 1 - - - 0 2 - - Vermont § - 0 2 - - - 0 1 - - - 0 1 - - Mid. Atlantic - 3 8 - 2 - 0 2 - - 6 2 1 3 4 6 1 2 New Jersey N 0 0 N N - 0 0 - - 1 3 8 1 1 New York (Upstate) - 1 5 - - - 0 2 - - 1 3 8 1 - New York City U 0 0 U U - 0 0 - - - 11- 0 2 - - - 0 1 - - - 7 23 - 6 Indiana - 2 11 - - - 0 2 - - - 1 5 - 1 Michigan - 0 3 - 2 - 0 1 - - - 2 10 - - Ohio 22 5 37 22 9 1 1 5 1 - 4 4 8 4 2 Wisconsin N 0 0 N N - 0 0 - - - 1 4 - 1 W.N. Central - 1 51 - - 1 0 10 1 - - 5 13 - 1 Iowa N 0 0 N N - 0 0 - - - 0 3 - - Kansas N 0 0 N N - 0 0 - - - 0 3 - - Minnesota - 0 50 - - - 0 10 - - - 0 2 - 1 Missouri - 1 3 - - - 0 1 - - - 3 8 - - Nebraska § - 0 1 - - - 0 0 - - - 0 2 - - North Dakota - 0 0 - - - 0 0 - - - 0 1 - - South Dakota - 0 3 - - 1 0 0 1 - - 0 3 - -
S. Atlantic

